CPT® Code 82378 is used to report the quantitative measurement of carcinoembryonic antigen (CEA) in blood. CEA is a tumor marker commonly used in the monitoring of certain cancers, particularly colorectal cancer, but may also be elevated in other malignancies and some benign conditions.
CEA testing is primarily used for disease monitoring rather than screening, helping providers assess treatment response, disease progression, and recurrence.
This code represents the laboratory assay only, not specimen collection or interpretation services, which may be reported separately when appropriate.
Key Facts About CPT® 82378
- Service type: Laboratory test (tumor marker)
- Test: Carcinoembryonic antigen (CEA), quantitative
- Specimen type: Serum or plasma
- Test purpose: Monitor cancer treatment response and recurrence
- Provider type: Laboratories, physicians, and qualified healthcare professionals
Common clinical indications:
- Monitoring colorectal cancer
- Assessing response to cancer treatment
- Surveillance for cancer recurrence
- Monitoring other malignancies (e.g., pancreatic, gastric, breast cancers in select cases)
- Evaluation of unexplained elevated tumor markers when clinically indicated
When to Use CPT® 82378
CPT 82378 is appropriate when:
- Measuring CEA levels for cancer monitoring or surveillance
- Tracking response to treatment in known malignancy
- Evaluating for recurrence of previously diagnosed cancer
- Supporting ongoing oncologic management decisions
Examples:
- Monitoring a patient undergoing treatment for colorectal cancer
- Following post-surgical surveillance for colon cancer recurrence
- Assessing response to chemotherapy in a patient with known malignancy
- Tracking rising CEA levels in a patient with cancer history
Documentation Requirements
To support CPT 82378 billing, documentation should include:
- Patient identifiers and date of service
- Clinical indication for testing (e.g., known malignancy)
- Specimen type (serum or plasma)
- Test performed (CEA quantitative measurement)
- Test result and date reported
- Ordering provider information
Clear documentation is essential to demonstrate medical necessity, especially since CEA is generally not used as a screening test.
Reimbursement and Coding Considerations
- CPT 82378 is typically covered when used for cancer monitoring or surveillance
- It is not generally indicated for cancer screening in asymptomatic individuals
- Diagnosis coding should reflect known malignancy or history of cancer
- Often ordered at regular intervals for established oncology follow-up
- Specimen collection may be billed separately if allowed by payer policy
Always verify payer-specific oncology and tumor marker testing guidelines before submitting claims.
How OptiMantra Supports Oncology and Laboratory Monitoring
OptiMantra’s integrated EMR and practice management system streamlines documentation and billing for CPT 82378:
With OptiMantra, providers can:
- Order tumor marker testing within the patient chart
- Link laboratory results to oncology diagnoses and treatment plans
- Maintain organized laboratory documentation that supports billing compliance and audit preparedness
- Support structured cancer surveillance workflows
- Coordinate follow-up testing and care plans within one platform
By centralizing oncology monitoring and lab workflows, OptiMantra helps practices improve efficiency, ensure compliance, and support continuity of care.
Try OptiMantra for free here!
Disclaimer: CPT® codes are maintained by the American Medical Association. This guide is for informational purposes only and does not replace official coding guidelines or payer policies.
.png)
